Active Phospholipase A2 Group VII (PLA2G7)
LpPLA2; PAF-AH; PAFAH; Lp-PLA2; LDL-PLA2; Platelet Activating Factor Acetylhydrolase,Plasma; Phospholipase A2,Group VII; LDL-associated phospholipase A2; Phospholipase A2, Lipoprotein Associated
- Product No.APA867Hu01
- Organism SpeciesHomo sapiens (Human) Same name, Different species.
- Buffer Formulation20mM Tris, 150mM NaCl, pH8.0, containing 1mM EDTA, 1mM DTT, 0.01% SKL, 5% Trehalose and Proclin300.
- Traits Freeze-dried powder
- Purity> 90%
- Isoelectric Point7.1
- ApplicationsCell culture; Activity Assays.
- DownloadInstruction Manual
- UOM 10µg50µg 200µg 1mg 5mg
For more details, please contact local distributors! US$ 600
For more details, please contact local distributors! US$ 1200
For more details, please contact local distributors! US$ 3600
For more details, please contact local distributors! US$ 9000
For more details, please contact local distributors!
Figure. The binding activity of LpPLA2 with PTPRN.
Phospholipase A2, Lipoprotein Associated (LpPLA2) also known as platelet-activating factor acetylhydrolase (PAF-AH) is a phospholipase A2 enzyme. LpPLA2 is platelet-activating factor (PAF) acetylhydrolase, a secreted enzyme that catalyzes the degradation of PAF to inactive products by hydrolysis of the acetyl group at the sn-2 position, producing the biologically inactive products LYSO-PAF and acetate. Besides, Protein Tyrosine Phosphatase Receptor Type N (PTPRN) has been identified as an interactor of LpPLA2, thus a binding ELISA assay was conducted to detect the interaction of recombinant human LpPLA2 and recombinant human PTPRN. Briefly, LpPLA2 were diluted serially in PBS, with 0.01% BSA (pH 7.4). Duplicate samples of 100uL were then transferred to PTPRN-coated microtiter wells and incubated for 2h at 37℃. Wells were washed with PBST and incubated for 1h with anti-LpPLA2 pAb, then aspirated and washed 3 times. After incubation with HRP labelled secondary antibody, wells were aspirated and washed 3 times. With the addition of substrate solution, wells were incubated 15-25 minutes at 37℃. Finally, add 50µL stop solution to the wells and read at 450nm immediately. The binding activity of LpPLA2 and PTPRN was shown in Figure 1, and this effect was in a dose dependent manner.
Reconstitute in 20mM Tris, 150mM NaCl (pH8.0) to a concentration of 0.1-1.0 mg/mL. Do not vortex.
Avoid repeated freeze/thaw cycles. Store at 2-8°C for one month. Aliquot and store at -80°C for 12 months.
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37°C for 48h, and no obvious degradation and precipitation were observed. The loss rate is less than 5% within the expiration date under appropriate storage condition.
- BCA Protein Quantification Kit
- Monoclonal Antibody Customized Service
- Polyclonal Antibody Customized Service
- Protein Activity Test Experiment Service
- Electrophoretic Mobility Shift Assay (EMSA) Experiment Service
- Lentivirus Packaging Experiment Service
- Adenovirus Packaging Experiment Service
- Real Time PCR Experimental Service
|Science & Sports||The effects of different intensity walking programs on serum blood lipids, high-sensitive C-reactive protein, and lipoprotein-associated phospholipase A2 in premenopausal women ScienceDirect: S0765159710000262|
|Metabolic Syndrome and Related Disorders||Association of Serum Lipoprotein-Associated Phospholipase A2 Level with Nonalcoholic Fatty Liver Disease Wiley: source|
|34||Effects of Pycnogenol on endothelial function in patients with stable coronary artery disease: a double-blind, randomized, placebo-controlled, cross-over study PubMed: 22240497|
|PLoS ONE||Effects of Lipid-Lowering Drugs on Irisin in Human Subjects In Vivo and in Human Skeletal Muscle Cells Ex Vivo PubMed: PMC3759413|
|China Pharmacy||Influence of Tongfengtai Granules on Inflammatory Factor in Acute Gouty Arthritis Model Rats Source|
|Atherosclerosis||Everolimus therapy is associated with reduced lipoprotein-associated phospholipase A2 (Lp-Pla2) activity and oxidative stress in heart transplant recipients. Pubmed: 23958269|
|Journal of Diabetes Research||Lipoprotein-Associated Phospholipase A2 Mass Level Is Increased in Elderly Subjects with Type 2 Diabetes Mellitus Hindawi: 278063|
|Health||The Role of Asymmetric Dimethylarginine and Lipoprotein Associated Phospholipase A2 in Children and Adolescents with Dyslipidemia Scirp:Source|
|Biology Bulletin||In vitro lipid-lowering and fibrinolytic effects of regulatory leucine-containing glyprolines in human blood Springer:Source|
|Gynecol Endocrinol.||Lipoprotein-associated phospholipase A2 and AGEs are associated with cardiovascular risk factors in women with history of gestational diabetes mellitus. Pubmed:24397392|
|Journal of Diabetes Research||Lipoprotein-Associated Phospholipase A 2 Mass Level Is Increased in Elderly Subjects with Type 2 Diabetes Mellitus Pubmed:24818163|
|Metabolism.||Effects of sitagliptin therapy on markers of low-grade inflammation and cell adhesion molecules in patients with type 2 diabetes Pubmed:25034387|
|J Am Heart Assoc||Effect of Extended‐Release Niacin on High‐Density Lipoprotein (HDL) Functionality, Lipoprotein Metabolism, and Mediators of Vascular Inflammation in Statin‐Treated Patients PubMed: 26374297|
|Czecho-Slovak Dermatology / Cesko-Slovenska Dermatologie||V Ebscohost|
|Endocrinol Metab (Seoul).||Effect of Pitavastatin Treatment on ApoB-48 and Lp-PLA2 in Patients with Metabolic Syndrome: Substudy of PROspective Comparative Clinical Study Evaluating the Efficacy and Safety of PITavastatin in Patients with Metabolic Syndrome pmc:PMC4803547|
|Clin Pharmacol Ther.||Effect of dipyridamole on myocardial reperfusion injury: A double‐blind randomized controlled trial in patients undergoing elective coronary artery bypass surgery Pubmed:25773594|
|Lipids in Health and Disease||Effect of intensive insulin treatment on plasma levels of lipoprotein-associated phospholipase A 2 and secretory phospholipase A 2 in patients with newly … articles:10.1186|
|Acta Endocrinologica||SERUM LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A2 IN MALES WITH METABOLIC SYNDROME AND OBSTRUCTIVE SLEEP APNEA. jrnl:1841098|
|Biomarker for diagnosis of moyamoya disease :|
|Catalog No.||Related products for research use of Homo sapiens (Human) Organism species||Applications (RESEARCH USE ONLY!)|
|APA867Hu01||Active Phospholipase A2 Group VII (PLA2G7)||Cell culture; Activity Assays.|
|RPA867Hu01||Recombinant Phospholipase A2 Group VII (PLA2G7)||Positive Control; Immunogen; SDS-PAGE; WB.|
|PAA867Hu01||Polyclonal Antibody to Phospholipase A2 Group VII (PLA2G7)||WB; IHC; ICC; IP.|
|LAA867Hu81||FITC-Linked Polyclonal Antibody to Phospholipase A2 Group VII (PLA2G7)||WB; IHC; ICC; IF.|
|LAA867Hu71||Biotin-Linked Polyclonal Antibody to Phospholipase A2 Group VII (PLA2G7)||WB; IHC; ICC.|
|MAA867Hu22||Monoclonal Antibody to Phospholipase A2 Group VII (PLA2G7)||WB; IHC; ICC; IP.|
|SEA867Hu||ELISA Kit for Phospholipase A2 Group VII (PLA2G7)||Enzyme-linked immunosorbent assay for Antigen Detection.|
|SCA867Hu||CLIA Kit for Phospholipase A2 Group VII (PLA2G7)||Chemiluminescent immunoassay for Antigen Detection.|